HealthDay News — The US Food and Drug Administration has announced a plan to revoke 52 food standards after concluding they ...

Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia receiving red blood cell (RBC) ...

In 2022, the FDA had made the decision to ban the products because the applications lacked sufficient evidence to show they met a public health standard.

HealthDay News — US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has removed two senior officials who were appointed by President Donald Trump. Heather Flick Melanson, chief of ...

HealthDay News — Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA Network Open.

New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now ...

The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted). Shingrix is indicated for the preven ...

HealthDay News — The US Food and Drug Administration has issued 7 warning letters to companies illegally marketing products containing 7-hydroxymitragynine (7-OH), which is found in trace amounts in ...

Greer Donley, a law professor at the University of Pittsburgh, said the ruling could change how states regulate other FDA-approved medication, including vaccines.

“Anticholinergics are associated with numerous adverse outcomes in older adults; therefore, it is essential for clinicians to avoid their use when possible, prescribe the lowest effective dose, and ...

In response to the CRL, the Company initiated a randomized, double-masked, vehicle-controlled dry eye chamber trial.

HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...